Meeting News
-
PACIFIC-R: Findings Reflect Clinical Reality of Consolidation Therapy in Stage III NSCLC
The real-world assessment of durvalumab in patients with unresectable stage III NSCLC in the PACIFIC-R trial has highlighted important differences between this population and that of the original randomized […]
-
Symposium Chairs Reflect on Current Status, Next Steps for Lung Cancer Screening on a Global Scale
It has been documented and accepted that lung cancer screening saves lives by detecting disease in high-risk individuals at earlier stages, making the disease more treatable and leading to improved […]
-
The “Holy Grail” of Lung Cancer Research: Bring the Immune System into Every Tumor
With multiple new therapies available, Prof. Johan Vansteenkiste says the search is on for biomarkers to better match patients to treatments.
-
Could the Daunting Biology of Small-Cell Lung Cancer Provide the Key to Elucidating Drug Resistance?
At ELCC 2021, Prof. Fiona Blackhall sees hope for improving patients’ poor prognoses on the horizon.
-
Statistical Design Flexibility Versus Optimism: The Example of KEYNOTE-604
In the era of targeted treatments and immunotherapies, it is relatively common to address multiple questions in a single phase III clinical trial. These questions often involve using more than […]
-
University of California, Davis, Thoracic Oncology Innovation Group to Again Host Latin American Oncologists for 3-Day Preceptorship
David R. Gandara, MD, past-president of the IASLC and director of Thoracic Oncology and senior advisor, UC Davis Comprehensive Cancer Center (UCDCCC), has always had a passion for mentorship, largely […]
-
Cell-free RNA Affords Another Tool in Lung Cancer Diagnosis and Treatment Monitoring
Although cell-free DNA (cfDNA) has emerged as the favored nucleic acid to analyze in liquid biopsy samples, there are situations when this marker fails to provided necessary information. In such cases, cell-free RNA (cfRNA) might help […]
-
Supporting the Detection of Early-Stage Disease with Use of Biomarkers
The NELSON trial and the US National Lung Cancer Screening Trial (NLST) marked major advances in lung cancer by establishing that low-dose computed tomography (LDCT) screening of high-risk individuals is effective at catching the disease in early […]
-
Leveraging ctDNA to Detect Minimal Residual Disease Following Surgery
Curative therapy remains elusive in early-stage NSCLC following surgical resection, sometimes even for patients with stage I disease. Adjuvant therapy can be of benefit, but only for a select few. As shown in the Lung Adjuvant […]
-
ctDNA Offers a Window Into Emerging Mechanisms of Resistance to Targeted Therapy
Targeted therapy has undoubtedly transformed the treatment landscape for metastatic NSCLC, with multiple agents now available to target seven different molecular drivers. In tandem with the growing treatment armamentarium, comprehensive molecular profiling has been critical in providing insight […]
View ILCN Archives
Provider Resources